Oncology Peer Review On-The-Go: Paolo Tarantino, MD, and Sara Tolaney, MD, Review Data in the Treatment of Breast Cancer at 2022 ASCO
Paolo Tarantino, MD, and Sara M. Tolaney, MD, MPH, spoke with CancerNetwork® about highlights from 2022 ASCO in breast cancer research.
In the inaugural Twitter Spaces edition of the Oncology Peer Review On-The-Go podcast hosted by CancerNetwork®, Paolo Tarantino, MD, a clinical research fellow at Dana-Farber Cancer Institute, and Sara M. Tolaney, MD, MPH, chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women’s Cancer at Dana-Farber as well as an associate professor of medicine at Harvard Medical School, reviewed presentations in breast cancer research from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
During the live event, Tarantino and Tolaney discussed the phase 3 DESTINY-Breast04 trial (NCT03734029), of fam-trastuzumab-nxki (Enhertu) vs chemotherapy for patients with HER2-low, hormone receptor–positive metastatic breast cancer. The co-hosts also reviewed surprising results from phase 3 PALOMA-2 trial (NCT01740427), which failed to show an overall survival benefit with use of palbociclib (Ibrance) plus letrozole in patients with estrogen receptor–positive/HER2-negative advanced breast cancer vs letrozole alone.
Additionally, Tolaney discussed her presentation of the phase 3 monarchE trial (NCT03155997) that explored adjuvant abemaciclib (Verzenio) in patients with hormone receptor–positive, HER2-negative, node-positive high-risk early breast cancer.
Overall, both investigators said they enjoyed coming back to in-person conferences and how they hope the trend of practice-changing trials continues with future conferences.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
